Last reviewed · How we verify
GnRHa combained with reverse addition therapy — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
GnRHa combained with reverse addition therapy (GnRHa combained with reverse addition therapy) — Shenzhen People's Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| GnRHa combained with reverse addition therapy TARGET | GnRHa combained with reverse addition therapy | Shenzhen People's Hospital | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- GnRHa combained with reverse addition therapy CI watch — RSS
- GnRHa combained with reverse addition therapy CI watch — Atom
- GnRHa combained with reverse addition therapy CI watch — JSON
- GnRHa combained with reverse addition therapy alone — RSS
Cite this brief
Drug Landscape (2026). GnRHa combained with reverse addition therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/gnrha-combained-with-reverse-addition-therapy. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab